Crizotinib Capsules Suppliers & Bulk Manufacturers

Available Forms: Oral Capsules

Available Strengths: 200 mg, 250 mg

Reference Brands: Xalkori® (US & EU)

Category: Oncology Cancer Care

Crizotinib Capsules is available in Oral Capsules and strengths such as 200 mg, 250 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Crizotinib Capsules is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Crizotinib Capsules can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Crizotinib Capsules are a targeted therapy used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) and ROS1-positive cancers, as well as anaplastic large cell lymphoma (ALCL). As a tyrosine kinase inhibitor (TKI), Crizotinib blocks the activity of abnormal proteins responsible for cancer cell growth. Marketed under Xalkori®, Crizotinib is available in 200 mg and 250 mg oral capsule strengths. Manufactured under GMP-compliant conditions, it offers a reliable solution for pharmaceutical distributors targeting US and EU oncology markets, providing effective treatment options for precision cancer medicine.